SUPPLEMENTARY INFORMATION TO THE STATEMENTS OF COMPREHENSIVE PROFIT OR LOST

12 Months Ended

Dec. 31, 2020

Disclosure of supplementary information to the statements of profit and lost and other comprehensive loss [Abstract]

SUPPLEMENTARY INFORMATION TO THE STATEMENTS OF COMPREHENSIVE PROFIT OR LOST

NOTE 22:- SUPPLEMENTARY INFORMATION TO THE STATEMENTS OF  COMPREHENSIVE PROFIT OR LOST

a. Additional information on Revenues:

Major customers:

BARDA and Vericel contributed 83% and 0% of the Company’s total revenues, in 2020, 34% and 55%, in 2019, and 0% and 0% in 2018, respectively. (see also Note 17).

No other customer contributed 10% or more of our Revenues in 2020 and 2019.

Revenue Re-classification:

Revenues from distributions agreements which recognized as right to access and does not have a stand alone value were classified as revenues from sale of products in the year ended 31, December 2018, 2019  in the amount of $176, $218 respectively.

Geographic information:

The Revenues reported in the financial statements are based on the location of the customers, as follows:

	Year ended December 31,
	2018		2019		2020
USA ( see also Note 17a, 17b)		-		28,504		18,030
EU and other international markets		3,401		3,285		3,733
		3,401		31,789		21,763

b. Cost of Revenues:

1. Cost of Revenues from sale of products

	Year ended December 31,
	2018			2019			2020
Salary and benefits (including share-based compensation)		2,212			1,916			2,139
Subcontractors		72			89			153
Depreciation and amortization		474			512			554
Cost of materials		468			456			704
Other manufacturing expenses		783			657			840
Decrease in inventory of finished products		299			344			155
Allotment of manufacturing costs to R&D		(2,220	)		(1,621	)		(1,394	)
		2,088			2,353			3,151

2. Cost of Revenues from development services

	Year ended December 31,
	2018		2019		2020
Salary and benefits		-		1,404		2,320
Subcontractors		-		7,412		8,747
		-		8,816		11,067

3. Cost of Revenues from license agreements

	Year ended December 31,
	2018		2019		2020
Royalties payments		-		680		-
		-		680		-

c. Research and development expenses, net of participations:

	Year ended December 31,
	2018			2019			2020
Salary and benefits (including share-based compensation)		3,703			2,965			2,094
Subcontractors		11,423			4,694			3,173
Depreciation and amortization		51			342			346
Cost of materials		309			311			517
Allotment of manufacturing costs		2,220			1,621			1,394
Other research and development expenses		209			137			174
Research and development, gross		17,915			10,070			7,698
Participations:
BARDA funds		(13,238	)		(3,785	)		-
Revaluation of liabilities in respect of IIA grants		(605	)		(1,316	)		-
		4,072			4,969			7,698

d.      Selling and marketing expenses:

	Year ended December 31,
	2018		2019		2020
Salary and benefits (including share based compensation) (1)		2,343		2,028		1,700
Marketing and medical support		1,055		1,298		740
Depreciation and amortization		9		49		82
Shipping and delivery		192		200		282
Registration and marketing license fees		589		489		424
		4,188		4,064		3,228

(1) The salary costs for the year ended December 31,2020 Includes one time payment of $243 derived from restructuring astrategy at the EU subsidery.

e. General and administrative expenses:

	Year ended December 31,
	2018		2019		2020
Salary and benefits (including share‑based compensation)		2,035		2,621		2,784
Professional fees		1,361		1,628		2,267
Depreciation and amortization		43		247		108
Other		360		746		300
		3,799		5,242		5,459

f. Other expenses:
The other one-time expenses amounted $751 and $1,172 for the years ended December 31, 2018 and 2019 respectivally, are associated with the review and assessment of the strategic deal.

g. Financial income and expense:

	Year ended December 31,
	2018		2019		2020
Financial income:
Interest income		412		434		297
Revaluation of liabilities in respect of the purchase of shares		-		-		433
Exchange differences, net		-		122		113
		412		556		843
Financial expense:
Interest in respect of IIA grants		892		925		832
Revaluation of liabilities in respect of IFRS16		-		140		144
Revaluation of liabilities in respect of the purchase of shares		758		1,690		-
Exchange differences, net		219		-		-
Finance expenses in respect of deferred Revenues		164		161		247
Other		84		67		56
		2,117		2,983		1,279